title: In vitro activities of DC-159a, a novel fluoroquinolone, against Mycobacterium species.
abstract: The in vitro activities of DC-159a against seven species of Mycobacterium were compared with moxifloxacin, gatifloxacin, levofloxacin, and rifampin. DC-159a was the most active compound against quinolone-resistant multidrug-resistant M. tuberculosis (MIC(90), 0.5 microg/ml) as well as drug-susceptible isolates (MIC(90), 0.06 microg/ml). The anti-tubercle bacilli activity of DC-159a was 4- to 32-fold more potent than those of currently available quinolones. DC-159a also demonstrated the highest activities against clinically important nontuberculous mycobacteria.
authors.affiliation: Research Institute of Tuberculosis, Japan Anti-Tuberculosis Association, Kiyose, Tokyo 204-8533, Japan.
authors.forename: Areeya
authors.initials: A
authors.lastname: Disratthakit
authors.forename: Norio
authors.initials: N
authors.lastname: Doi
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology*; D000995:Antitubercular Agents / Q000494:pharmacology*; D001372:Aza Compounds / Q000494:pharmacology; D024901:Drug Resistance, Multiple, Bacterial; D024841:Fluoroquinolones / Q000494:pharmacology*; D000077734:Gatifloxacin; D006801:Humans; D066298:In Vitro Techniques; D064704:Levofloxacin; D008826:Microbial Sensitivity Tests; D000077266:Moxifloxacin; D009161:Mycobacterium / Q000145:classification / Q000187:drug effects* / Q000302:isolation & purification; D009164:Mycobacterium Infections / Q000188:drug therapy / Q000382:microbiology; D015269:Mycobacterium avium Complex / Q000187:drug effects / Q000302:isolation & purification; D016926:Mycobacterium chelonae / Q000187:drug effects / Q000302:isolation & purification; D019907:Mycobacterium fortuitum / Q000187:drug effects / Q000302:isolation & purification; D019909:Mycobacterium kansasii / Q000187:drug effects / Q000302:isolation & purification; D009169:Mycobacterium tuberculosis / Q000187:drug effects / Q000302:isolation & purification; D009170:Nontuberculous Mycobacteria / Q000187:drug effects / Q000302:isolation & purification; D015242:Ofloxacin / Q000494:pharmacology; D011804:Quinolines / Q000494:pharmacology; D012293:Rifampin / Q000494:pharmacology; D013045:Species Specificity
chemical_list: C530475:7-(7-amino-7-methyl-5-azaspiro(2.4)heptan-5-yl)-6-fluoro-1-(2-fluoro-1-cyclopropyl)-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid; D000631:Aminopyridines; D000995:Antitubercular Agents; D001372:Aza Compounds; D024841:Fluoroquinolones; D011804:Quinolines; D064704:Levofloxacin; D015242:Ofloxacin; D000077734:Gatifloxacin; D000077266:Moxifloxacin; D012293:Rifampin